WO/2006/127319 FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME||WO||30.11.2006|
||PCT/US2006/018737||MERCK & CO., INC.||WONG, Jeannie Chow|
The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
WO/2006/028590 1,1,2,2-TETRA (HETERO) ARYLETHANES OR 1,1,2-TRI (HETERO) ARYL-2-HETEROCYCLYLETHANES AS POTASSIUM CHANNEL INHIBITORS||WO||16.03.2006|
||PCT/US2005/026334||MERCK & CO., INC.||BILODEAU, Mark, T.|
The present invention relates to compounds having the structure Formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias.
WO/2006/026135 SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES||WO||09.03.2006|
||PCT/US2005/028969||NEUROGEN CORPORATION||BLUM, Charles, A.|
Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula (I): wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
WO/2006/021806 ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS||WO||02.03.2006|
||PCT/GB2005/003353||MERCK SHARP & DOHME LIMITED||GILLIGAN, Myra|
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.
WO/2006/014357 CETP INHIBITORS||WO||09.02.2006|
||PCT/US2005/023546||MERCK & CO., INC.||ALI, Amjad|
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalky substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalky substituent connected directly to the ring or attached to the ring through a -CH2-.
WO/2006/012725 LYSINE BASED COMPOUNDS||WO||09.02.2006|
||PCT/CA2004/001440||AMBRILIA BIOPHARMA INC.||STRANIX, Brent, Richard|
The present invention provides lysine based compounds of the formula (I); and when the compound of formula (I) comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein Rl may be, for example, (HO)2P(O)-, (NaO)2P(O)-, alkylCO- or cycloalkyl-CO-, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein. These lysine based compounds have a physiologically cleavable unit, namely R1 , whereby upon cleavage of the unit, an HIV aspartyl protease inhibitor is released,
WO/2006/005104 DIRECT CURRENCY CONVERSION||WO||19.01.2006|
This invention concerns direct currency conversion, that is automatic currency conversion at point of payment for card transactions. In particular it concerns a method for operating equipment associated with a financial transaction. The method includes the steps of: Presenting a card related to a customer's account. Recording a card number from the card. Applying all or part of the card number to a tree structure, and automatically processing that number by the tree one bit at a time to arrive at an end node of the tree coded with information related to the currency of the customer's card account. Determining the currency of the customer's card account. Comparing the currency of the customer's card account with one or more currencies predetermined for the equipment. Where the comparison indicates different currencies, providing direct currency conversion services. In other aspects it concerns the equipment itself, and a method of preparing a tree structure for use by the equipment.
WO/2005/123123 THERAPEUTIC REPROGRAMMING, HYBRID STEM CELLS AND MATURATION||WO||29.12.2005|
||PCT/US2005/005052||PRIMEGEN BIOTECH LLC||SAYRE, Chauncey, B.|
Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy and have the potential to differentiate into more committed cell lineages. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cellular regenerative therapy are provided.
WO/2005/123901 STEM CELL MATURATION FOR ALL TISSUE LINES||WO||29.12.2005|
||PCT/US2005/002487||PRIMEGEN BIOTECH LLC||SAYRE, Chauncey, B.|
The present invention provides a hybrid stem comprising an enucleated adult stem cell having a nucleus derived from a primordial sex cell or an embryonic stem cell. The primordial sex cell may be a spermatogonia or an oogonia from a donor animal or mammal. The enucleated adult stem cell may be fused to a primordial sex cell or an embryonic stem cell by many methods including but not limited to electrofusion, virus-based fusion methodology, chemical fusion or mechanical-based fusion.
WO/2005/120477 N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS||WO||22.12.2005|
||PCT/US2005/019554||MERCK & CO., INC.||HANNEY, Barbara|
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzhheiner’s disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.